HomeClinical TopicsFDA approves first biosimilar for treatment of cancer

FDA approves first biosimilar for treatment of cancer

On Sept. 14, the U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

Read More at FDA.gov

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

covid-19 virus illustration

Will Omicron Be More Contagious Than Delta?

If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...